JP2023532273A - 二重特異性スーパーカイン及びその使用 - Google Patents

二重特異性スーパーカイン及びその使用 Download PDF

Info

Publication number
JP2023532273A
JP2023532273A JP2022579927A JP2022579927A JP2023532273A JP 2023532273 A JP2023532273 A JP 2023532273A JP 2022579927 A JP2022579927 A JP 2022579927A JP 2022579927 A JP2022579927 A JP 2022579927A JP 2023532273 A JP2023532273 A JP 2023532273A
Authority
JP
Japan
Prior art keywords
seq
cancer
cells
mutein
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532273A5 (cg-RX-API-DMAC7.html
Inventor
ファハル マーチャント
Original Assignee
メディシナ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディシナ セラピューティクス インコーポレイテッド filed Critical メディシナ セラピューティクス インコーポレイテッド
Publication of JP2023532273A publication Critical patent/JP2023532273A/ja
Publication of JP2023532273A5 publication Critical patent/JP2023532273A5/ja
Priority to JP2026064153A priority Critical patent/JP2026120639A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2022579927A 2020-06-24 2021-06-24 二重特異性スーパーカイン及びその使用 Pending JP2023532273A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026064153A JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063043227P 2020-06-24 2020-06-24
US63/043,227 2020-06-24
US202063093724P 2020-10-19 2020-10-19
US63/093,724 2020-10-19
US202063094322P 2020-10-20 2020-10-20
US63/094,322 2020-10-20
US202163165600P 2021-03-24 2021-03-24
US202163165738P 2021-03-24 2021-03-24
US63/165,600 2021-03-24
US63/165,738 2021-03-24
PCT/CA2021/050872 WO2021258213A1 (en) 2020-06-24 2021-06-24 Bifunctional superkines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026064153A Division JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Publications (2)

Publication Number Publication Date
JP2023532273A true JP2023532273A (ja) 2023-07-27
JP2023532273A5 JP2023532273A5 (cg-RX-API-DMAC7.html) 2024-07-01

Family

ID=79282489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022579927A Pending JP2023532273A (ja) 2020-06-24 2021-06-24 二重特異性スーパーカイン及びその使用
JP2026064153A Pending JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026064153A Pending JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Country Status (6)

Country Link
US (1) US20230365642A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172216A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023532273A (cg-RX-API-DMAC7.html)
CN (1) CN116390744A (cg-RX-API-DMAC7.html)
CA (1) CA3183825A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021258213A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015KN00329A (cg-RX-API-DMAC7.html) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−4受容体結合融合タンパク質及びその使用
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP7819944B2 (ja) * 2020-07-09 2026-02-25 ユーティレックス カンパニー リミテッド Il-2バリアント
US12702710B2 (en) 2020-10-12 2026-08-11 Medicenna Therapeutics Inc. Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
KR20250004954A (ko) * 2022-03-08 2025-01-09 메디세나 테라퓨틱스, 인크. Il-2, il-13, 및 il-4 시토킨 이작용성 분자의 용도 및 방법
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023248009A1 (en) * 2022-06-21 2023-12-28 Medicenna Therapeutics, Inc. Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
CN121816367A (zh) * 2023-06-27 2026-04-07 梅迪塞纳医疗股份有限公司 Il-2融合蛋白
EP4770754A1 (en) 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (en) * 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
WO2018234862A1 (en) * 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019239213A2 (en) * 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2019232523A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
TW202128961A (zh) * 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (en) * 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
WO2018234862A1 (en) * 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途

Also Published As

Publication number Publication date
EP4172216A4 (en) 2024-12-04
US20230365642A1 (en) 2023-11-16
CA3183825A1 (en) 2021-12-30
WO2021258213A1 (en) 2021-12-30
JP2026120639A (ja) 2026-07-22
EP4172216A1 (en) 2023-05-03
CN116390744A (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
US12338269B2 (en) IL-2 superagonists in combination with anti-PD-1 antibodies
US20230365642A1 (en) Bifunctional superkines and uses thereof
JP7288405B2 (ja) ヒトドメインを有する抗b細胞成熟抗原キメラ抗原受容体
US11034763B2 (en) Flag tagged CD19-CAR-T cells
EP4353750A2 (en) Chimeric antigen receptors (cars), compositions and methods thereof
KR20240046644A (ko) 고형암을 위한 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
CN108697745A (zh) 编码抗tcr复合体抗体或片段的b组腺病毒
US20220347268A1 (en) Il-4r as a biomarker in cancer
US12404497B2 (en) Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
WO2022007795A1 (zh) 一种嵌合受体及其应用
WO2023248009A1 (en) Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
US20250387474A1 (en) Uses and methods for il-2, il-13, and il-4 cytokine bifunctional molecules
CN115807020A (zh) 白介素15受体α装甲CAR-T细胞在降低白介素15诱导的细胞毒性中的用途
EP4423283A1 (en) Chimeric adaptor polypeptides
WO2024148369A1 (en) Targeted il-12 affinity variants
KR20260030127A (ko) Il-12 안정성 변이체
CN119591728A (zh) 靶向bcma和cd19的双特异性嵌合抗原受体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804